S-1: Phio Pharmaceuticals Files $100 Million Shelf Registration for Future Offerings

Phio Pharmaceuticals aims to raise up to $100 million through a shelf registration, offering various securities to fund clinical development and corporate activities.

Summary

• Phio Pharmaceuticals has filed a Form S-3 registration statement with the SEC to offer up to $100 million in securities.
• The offering includes common stock, preferred stock, debt securities, warrants, and units.
• The company intends to use the net proceeds for general corporate purposes, including funding preclinical and clinical development, research and development activities, and general and administrative expenses.
• A portion of the proceeds may also be used to pay off outstanding debt or acquire complementary businesses, products, and technologies.
• The company's common stock trades on the Nasdaq Capital Market under the symbol PHIO, with a closing price of $0.7324 per share on May 16, 2024.
• As of May 16, 2024, the aggregate market value of the company's outstanding common stock held by non-affiliates was approximately $4,884,163 million.
• The company has sold approximately $1,621,005 million of securities pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month period that ends on and includes the date of this prospectus.
• The company may sell the securities from time to time in one or more offerings directly to investors, through agents, or through underwriters and dealers.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily outlining the details of a shelf registration. While it highlights potential benefits of the company's technology, it also acknowledges significant risks and uncertainties. The sentiment is moderately positive due to the potential for future growth and development, but tempered by the inherent risks associated with early-stage biotechnology companies.

Positives

• The shelf registration provides Phio Pharmaceuticals with financial flexibility to raise capital as needed.
• The company has a proprietary INTASYL small interfering RNA gene silencing technology.
• The company is currently evaluating PH-762 in a Phase 1b dose-escalating clinical trial for the treatment of patients with cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
• The first two patients enrolled in our first cohort have completed treatment with PH-762 with no reported adverse events.

Negatives

• The company is dependent on the success of its INTASYL technology platform, which is unproven and may never lead to approved and marketable products.
• The company's product candidates are in an early stage of development and the company may fail, experience significant delays, never advance in clinical development or not be successful in its efforts to identify or discover additional product candidates, which may materially and adversely impact the company's business.
• The company will require substantial additional funds to complete its research and development activities.
• The company may not be able to regain compliance with the continued listing requirements of The Nasdaq Capital Market.
• The price of the company's common stock has been and may continue to be volatile.

Risks

• The company's success depends on the INTASYL technology platform, which is unproven.
• Product candidates are in early development stages and may face delays or failure.
• The company relies on third parties for manufacturing clinical supplies.
• The company is dependent on the patents it owns and the technologies it licenses, and if it fails to maintain its patents or lose the right to license such technologies, its ability to develop new products would be harmed.
• The company needs substantial additional funding for research and development.
• Future financing may be obtained through the issuance of debt or equity, which may have an adverse effect on the company's stockholders or may otherwise adversely affect the company's business.
• The company may not be able to regain compliance with the continued listing requirements of The Nasdaq Capital Market.
• The price of the company's common stock has been and may continue to be volatile.

Future Outlook

The company anticipates using the net proceeds from the sale of securities for general corporate purposes, including funding preclinical and clinical development, other research and development activities, and for general and administrative expenses. They may also use a portion of the net proceeds to pay off outstanding indebtedness, if any, and/or acquire or invest in complementary businesses, products and technologies.

Industry Context

Phio Pharmaceuticals is operating in the competitive immuno-oncology space, focusing on RNAi-based therapeutics. The company's INTASYL platform aims to improve immune cell effectiveness in killing tumor cells, addressing a key challenge in cancer immunotherapy.

Comparison to Industry Standards

• Phio Pharmaceuticals' approach of using self-delivering RNAi technology differs from other siRNA technologies that require cell-targeting chemical conjugates, such as those used by Alnylam Pharmaceuticals.
• The company's focus on direct-to-tumor injection of PH-762 is similar to approaches being explored by companies like Replimune, which uses oncolytic viruses for local immune stimulation.
• Phio's collaboration with AgonOx to develop a T cell-based therapy is in line with the broader industry trend of combining different immunotherapeutic modalities, as seen with companies like Iovance Biotherapeutics in the adoptive cell therapy space.

Stakeholder Impact

• Shareholders may experience dilution if the company issues new shares of common stock.
• Employees may benefit from increased funding for research and development.
• Customers (patients) may benefit from the development of new therapies.
• Suppliers and creditors may benefit from the company's increased financial stability.

Next Steps

• The company may offer and sell securities from time to time under this prospectus.
• The company will describe the specific terms of the securities in a prospectus supplement or sales agreement prospectus.
• The company expects to complete enrollment of patients in the second cohort of the Phase 1b clinical trial with PH-762 in the second quarter of 2025.

Key Dates

Keywords

Phio Pharmaceuticals, shelf registration, common stock, preferred stock, debt securities, warrants, units, INTASYL, PH-762, clinical trial, immuno-oncology, RNAi, securities, offering